Tscan Therapeutics, Inc. ( (TCRX) ) has released its Q3 earnings. Here is a breakdown of the information Tscan Therapeutics, Inc. presented to its investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
TScan Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, focused on developing T cell receptor-engineered T cell therapy products for cancer treatment. In its latest earnings report, TScan Therapeutics highlighted a significant increase in collaboration and license revenue, reaching $7.8 million for the nine months ended September 30, 2025, compared to $2.1 million in the same period in 2024. However, the company reported a net loss of $106.8 million, up from $91.7 million the previous year, primarily due to increased research and development expenses. The company’s cash and cash equivalents stood at $169.5 million, with total assets amounting to $262.2 million. Despite the losses, TScan remains committed to advancing its TCR-T therapy product candidates, with management expressing confidence in its current capital resources to support operations for at least the next 12 months. Looking ahead, the company aims to continue its research and development efforts and explore strategic partnerships to enhance its financial position and product pipeline.